Related Experiment Video
Updated: Jan 9, 2026
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Human metapneumovirus: Insights into immune evasion, pathogenesis and liposome-based vaccine strategies
Fahad Alhumaydhi1, Mohammad Hamza Khan2, Masood Alam Khan3
1Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia.
Abstract:
Human Metapneumovirus (HMPV) remains a major contributor to respiratory diseases, particularly affecting infants, the elderly, and immunocompromised individuals. HMPV, first identified in 2001, has been a prominent cause of respiratory tract infections, ranging from mild upper respiratory symptoms to severe pneumonia and bronchiolitis. Despite its impact, there are currently no licensed vaccines or specific antivirals treatments targeting HMPV. The virus evades host immunity by suppressing interferon signaling through pathways such as RIG-I/MAVS and JAK-STAT, and by impairing dendritic cell maturation, which collectively delays adaptive immunity. Vaccine development efforts focus on live-attenuated, subunit, viral vector-based, and mRNA platforms, with the F protein identified as the primary target for eliciting neutralizing antibodies. Advancements such as lipid nanoparticles and virus-like particles have enhanced vaccine delivery and immunogenicity. Understanding HMPV-host immune interactions is essential for reducing the global disease burden and advancing both novel preventive and therapeutic interventions. This review consolidates current knowledge on HMPV virology, immune evasion, and vaccine development while highlighting emerging diagnostic innovations and multivalent vaccine platforms. Global research collaboration remains crucial in combating HMPV-related respiratory diseases and improving preventive strategies. Future directions emphasize to develop multivalent vaccines against multiple respiratory viruses, the optimization of adjuvants, and the deployment of modular vaccine platforms to address antigenic variability.
Insights
Human Metapneumovirus (HMPV) causes significant respiratory illness, especially in vulnerable groups. Current research focuses on developing vaccines and treatments by understanding HMPV
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Human Metapneumovirus (HMPV) is a key cause of respiratory infections in infants, elderly, and immunocompromised individuals.
- HMPV infection presents a spectrum of illness from mild symptoms to severe pneumonia and bronchiolitis.
- No licensed vaccines or specific antiviral therapies currently exist for HMPV.
Purpose of the Study:
- To review current knowledge on HMPV virology, immune evasion mechanisms, and vaccine development strategies.
- To highlight advancements in diagnostics and multivalent vaccine platforms for HMPV.
- To emphasize the importance of understanding HMPV-host interactions for disease control.
Main Methods:
- Literature review consolidating research on HMPV.
- Analysis of HMPV's immune evasion strategies, including interferon signaling suppression and dendritic cell maturation impairment.
- Examination of various vaccine platforms targeting the HMPV F protein.
Main Results:
- HMPV effectively evades host immunity by interfering with interferon signaling and dendritic cell function.
- Vaccine development is exploring live-attenuated, subunit, viral vector, and mRNA platforms, with the F protein as a key target.
- Novel delivery systems like lipid nanoparticles and virus-like particles show promise for enhanced immunogenicity.
Conclusions:
- Understanding HMPV's interaction with the host immune system is critical for developing effective interventions.
- Future HMPV research should focus on multivalent vaccines, optimized adjuvants, and modular platforms to address viral variability.
- Global collaboration is essential to combat HMPV-related respiratory diseases and improve public health outcomes.
